Plasma adiponectin, visfatin, leptin, and resistin levels and the onset of colonic polyps in patients with prediabetes
Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine l...
Saved in:
| Published in | BMC endocrine disorders Vol. 20; no. 1; pp. 63 - 12 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
11.05.2020
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1472-6823 1472-6823 |
| DOI | 10.1186/s12902-020-0540-7 |
Cover
| Abstract | Background
Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects.
Methods
A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed.
Results
Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L,
P
= 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L,
P
= 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L,
P
= 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L,
P
< 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (
P
= 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all
P
> 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects.
Conclusions
Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. |
|---|---|
| AbstractList | Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects.
A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed.
Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects.
Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 [+ or -] 4.8 vs 13.3 [+ or -] 3.9) mg/L, P = 0.013; prediabetes (5.6 [+ or -] 3.7 vs 9.2 [+ or -] 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 [+ or -] 2.6 vs 6.7 [+ or -] 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 [+ or -] 2.9 vs 7.4 [+ or -] 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. Methods A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Results Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 [+ or -] 4.8 vs 13.3 [+ or -] 3.9) mg/L, P = 0.013; prediabetes (5.6 [+ or -] 3.7 vs 9.2 [+ or -] 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 [+ or -] 2.6 vs 6.7 [+ or -] 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 [+ or -] 2.9 vs 7.4 [+ or -] 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Conclusions Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Keywords: Prediabetes, Colonic polyps, Adipokine, Risk factors Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. Methods A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Results Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Conclusions Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Abstract Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. Methods A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Results Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Conclusions Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects.BACKGROUNDPrediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects.A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed.METHODSA total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed.Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects.RESULTSPlasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups (P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects.Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects.CONCLUSIONSPlasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines, is an independent influencing factor for colonic polyps in prediabetes subjects. However, the correlation between adipocytokine levels and colonic polyps in prediabetes subjects is unclear. This research explores the relationship between plasma adiponectin, visfatin, leptin, and resistin levels and the development of colonic polyps in prediabetes subjects. Methods A total of 468 prediabetes subjects who underwent electronic colonoscopy examinations were enrolled in this study; there were 248 cases of colonic polyps and 220 cases without colonic mucosal lesions. Then, colonic polyps patients with prediabetes were subdivided into a single-polyp group, multiple-polyps group, low-risk polyps group, or high-risk polyps group. In addition, 108 subjects with normal glucose tolerance who were frequency matched with prediabetes subjects by sex and age were selected as the control group; 46 control subjects had polyps, and 62 control subjects were polyp-free. Plasma adiponectin, visfatin, leptin, and resistin levels were measured in all the subjects, and the related risk factors of colonic polyps in prediabetes subjects were analysed. Results Plasma adiponectin levels were significantly lower in the polyps group than in the polyp-free group [normal glucose tolerance (9.8 ± 4.8 vs 13.3 ± 3.9) mg/L, P = 0.013; prediabetes (5.6 ± 3.7 vs 9.2 ± 4.4) mg/L, P = 0.007]. In prediabetes subjects, plasma adiponectin levels were decreased significantly in the multiple polyps group [(4.3 ± 2.6 vs 6.7 ± 3.9) mg/L, P = 0.031] and the high-risk polyps group [(3.7 ± 2.9 vs 7.4 ± 3.5) mg/L, P < 0.001] compared to their control groups. Plasma visfatin levels were higher in the polyps group and the multiple-polyps group than those in their control groups ( P = 0.041 and 0.042, respectively), and no significant difference in plasma leptin and resistin levels was observed between these three pairs of groups (all P > 0.05). The multivariate logistic regression analysis showed that lower levels of plasma adiponectin was a risk factor for colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. Conclusions Plasma adiponectin levels are inversely associated with colonic polyps, multiple colonic polyps, and high-risk colonic polyps in prediabetes subjects. And adiponectin may be involved in the development of colon tumours in prediabetes subjects. |
| ArticleNumber | 63 |
| Audience | Academic |
| Author | Zhang, Qunhui Ji, Hua Chen, Ruofei Chen, Mingwei Deng, Lili Zhao, Xiaotong Wang, Yalei |
| Author_xml | – sequence: 1 givenname: Lili surname: Deng fullname: Deng, Lili organization: Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University – sequence: 2 givenname: Xiaotong surname: Zhao fullname: Zhao, Xiaotong organization: Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University – sequence: 3 givenname: Mingwei orcidid: 0000-0002-6588-3903 surname: Chen fullname: Chen, Mingwei email: chmw1@163.com organization: Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University, Institute of Traditional Chinese Medicine for the Prevention and Control of Diabetes, Anhui Academy of Chinese Medicine – sequence: 4 givenname: Hua surname: Ji fullname: Ji, Hua organization: Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University – sequence: 5 givenname: Qunhui surname: Zhang fullname: Zhang, Qunhui organization: Department of Endocrinology, the First Affiliated Hospital of Anhui Medical University – sequence: 6 givenname: Ruofei surname: Chen fullname: Chen, Ruofei organization: Anhui Medical University Clinical College – sequence: 7 givenname: Yalei surname: Wang fullname: Wang, Yalei organization: Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32393372$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB_wA9igSGxYkOLXOMkGqap4VKoEC1hbzs31jEcZO9iZqfrvuTNT2k4FJAs7N985zr05p8VRiAGL4jVn55w3-kPmomWiYoJVbKZYVT8rTriqRaUbIY8e7Y-L05yXjPG6EexFcSyFbKWsxUmx-T7YvLKl7f1I5jD58L7c-OzsbjfguFtt6MuE2Wd6ouIGh7yrTQssY8g4ldGVEIcYPJRjHG7HXBI5kguGKZc3flqUY8Le2w4nzC-L584OGV_drWfFz8-fflx-ra6_fbm6vLiuQDM5VbZzMONOg6ytZKxtQSrUPShUQs-kk1aB41qAk01nueMdXSg5opwB6FaeFVd73z7apRmTX9l0a6L1ZleIaW5smjwMaJxtZnXbQ6dBq663LfTQtqKlGXaN6oC8Pu69xnW3wh6osWSHA9PDN8EvzDxuTC24VmL7Me_uDFL8tcY8mZXPgMNgA8Z1NkIx3vBaak3o2yfoMq5ToFFtKaWo51o8UHNLDfjgIp0LW1NzQYCiS3Oizv9C0d3jygP9dOepfiB487jR-w7_pIYAvgcgxZwTunuEM7NNptkn01AyzTaZpiZN_UQDfqJ4xO2s_PBfpdgrM50S5pgeZvFv0W9Q7Pgf |
| CitedBy_id | crossref_primary_10_3390_jpm12050735 crossref_primary_10_1016_j_cytogfr_2021_10_006 crossref_primary_10_1080_01635581_2023_2272343 crossref_primary_10_3389_fendo_2022_774272 crossref_primary_10_3390_biology13100821 crossref_primary_10_3390_cells13080663 crossref_primary_10_3390_ijms232113128 crossref_primary_10_7759_cureus_65403 crossref_primary_10_1016_j_canep_2021_101958 crossref_primary_10_12677_wjcr_2024_142013 crossref_primary_10_3389_fgene_2023_1139626 crossref_primary_10_3390_ijms21218308 |
| Cites_doi | 10.1210/jc.2017-00954 10.1158/1055-9965.EPI-07-0199 10.1055/s-0029-1242458 10.1371/journal.pone.0085939 10.1001/jama.290.22.2959 10.1016/j.atherosclerosis.2016.11.003 10.1016/j.critrevonc.2017.06.003 10.3760/cma.j.issn.1000-6699.2015.10.005 10.1007/s00592-018-1144-9 10.1002/ijc.25516 10.1007/s12032-012-0280-2 10.2741/E596 10.1210/jc.2008-1091 10.1007/s00125-010-1796-7 10.1007/s13668-012-0036-9 10.1042/BSR20170945 10.7314/APJCP.2014.15.1.397 10.1136/gut.2008.159293 10.1159/000323136 10.1007/s10620-013-2591-3 10.1007/s11670-009-0142-4 10.1053/j.gastro.2008.02.002 10.1111/ajco.12090 10.1002/jcp.24248 10.1007/978-3-319-42542-9_2 10.1016/j.dsx.2019.02.023 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12902-020-0540-7 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1472-6823 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_fa8579dcb6c64bda9cdc9929472b84bc PMC7216429 A627444461 32393372 10_1186_s12902_020_0540_7 |
| Genre | Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: the Chinese Medical Association Clinical Special Fund grantid: 12020320320322 – fundername: Natural Science Foundation of Anhui Province grantid: 1508085MH150 funderid: http://dx.doi.org/10.13039/501100003995 – fundername: Natural Science Foundation of Anhui Province grantid: 1508085MH150 – fundername: ; grantid: 1508085MH150 – fundername: ; grantid: 12020320320322 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QP 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-abfc51f6c37a30099c34e6dc4e42653f3a4cf162cf38ba1f1bbbbe31ee35cc693 |
| IEDL.DBID | M48 |
| ISSN | 1472-6823 |
| IngestDate | Wed Aug 27 00:45:29 EDT 2025 Tue Sep 09 03:26:27 EDT 2025 Fri Sep 05 08:24:16 EDT 2025 Fri Jul 25 06:27:51 EDT 2025 Tue Jun 17 21:29:47 EDT 2025 Tue Jun 10 20:49:47 EDT 2025 Thu Apr 03 07:08:24 EDT 2025 Tue Jul 01 01:37:12 EDT 2025 Thu Apr 24 23:05:25 EDT 2025 Sat Sep 06 07:29:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Adipokine Prediabetes Colonic polyps Risk factors |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-abfc51f6c37a30099c34e6dc4e42653f3a4cf162cf38ba1f1bbbbe31ee35cc693 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-6588-3903 |
| OpenAccessLink | https://www.proquest.com/docview/2404416272?pq-origsite=%requestingapplication% |
| PMID | 32393372 |
| PQID | 2404416272 |
| PQPubID | 44656 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fa8579dcb6c64bda9cdc9929472b84bc pubmedcentral_primary_oai_pubmedcentral_nih_gov_7216429 proquest_miscellaneous_2401817366 proquest_journals_2404416272 gale_infotracmisc_A627444461 gale_infotracacademiconefile_A627444461 pubmed_primary_32393372 crossref_primary_10_1186_s12902_020_0540_7 crossref_citationtrail_10_1186_s12902_020_0540_7 springer_journals_10_1186_s12902_020_0540_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-11 |
| PublicationDateYYYYMMDD | 2020-05-11 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC endocrine disorders |
| PublicationTitleAbbrev | BMC Endocr Disord |
| PublicationTitleAlternate | BMC Endocr Disord |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | C Jochem (540_CR18) 2016; 208 FA Haggar (540_CR19) 2009; 22 540_CR16 S Muppala (540_CR23) 2017; 116 JH Kim (540_CR9) 2007; 16 DP Antonino (540_CR2) 2017; 102 SS Comstock (540_CR10) 2014; 9 MA de Graaf (540_CR27) 2011; 118 MW Chen (540_CR14) 2015; 31 T Fujisawa (540_CR22) 2008; 57 R Scicali (540_CR21) 2018; 55 J Ferlay (540_CR5) 2010; 127 K Aleksandrova (540_CR11) 2013; 5 VR Aroda (540_CR1) 2008; 93 XH Zhou (540_CR4) 2010; 53 WS Huang (540_CR24) 2013; 228 R Scicali (540_CR3) 2016; 255 RK Joshi (540_CR12) 2014; 15 JM Cha (540_CR6) 2013; 58 540_CR7 M Chen (540_CR13) 2016; 12 K Aleksandrova (540_CR8) 2013; 2 B Levin (540_CR17) 2008; 134 A Kumor (540_CR26) 2009; 24 JC Cong (540_CR25) 2009; 21 MM Adeva-Andany (540_CR20) 2019; 13 MW Chen (540_CR15) 2012; 29 |
| References_xml | – volume: 102 start-page: 3756 issue: 10 year: 2017 ident: 540_CR2 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2017-00954 – volume: 16 start-page: 1534 issue: 8 year: 2007 ident: 540_CR9 publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-07-0199 – volume: 22 start-page: 191 issue: 4 year: 2009 ident: 540_CR19 publication-title: Clin Colon Rectal Surg doi: 10.1055/s-0029-1242458 – volume: 9 start-page: e85939 issue: 1 year: 2014 ident: 540_CR10 publication-title: PLoS One doi: 10.1371/journal.pone.0085939 – ident: 540_CR16 doi: 10.1001/jama.290.22.2959 – volume: 255 start-page: 102 year: 2016 ident: 540_CR3 publication-title: Atherosclerosis. doi: 10.1016/j.atherosclerosis.2016.11.003 – volume: 116 start-page: 125 year: 2017 ident: 540_CR23 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2017.06.003 – volume: 31 start-page: 851 issue: 10 year: 2015 ident: 540_CR14 publication-title: Chin J Endocrinol and Metab doi: 10.3760/cma.j.issn.1000-6699.2015.10.005 – volume: 55 start-page: 741 issue: 7 year: 2018 ident: 540_CR21 publication-title: Acta Diabetol doi: 10.1007/s00592-018-1144-9 – volume: 127 start-page: 2893 issue: 12 year: 2010 ident: 540_CR5 publication-title: Int J Cancer doi: 10.1002/ijc.25516 – volume: 29 start-page: 3129 year: 2012 ident: 540_CR15 publication-title: Med Oncol doi: 10.1007/s12032-012-0280-2 – volume: 5 start-page: 61 year: 2013 ident: 540_CR11 publication-title: Front Biosci (Elite Ed) doi: 10.2741/E596 – volume: 24 start-page: 275 issue: 3 year: 2009 ident: 540_CR26 publication-title: Int J Colorectal Dis – volume: 93 start-page: 3259 issue: 9 year: 2008 ident: 540_CR1 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-1091 – volume: 53 start-page: 1867 issue: 9 year: 2010 ident: 540_CR4 publication-title: Diabetologia. doi: 10.1007/s00125-010-1796-7 – volume: 2 start-page: 1 issue: 1 year: 2013 ident: 540_CR8 publication-title: Curr Nutr Rep doi: 10.1007/s13668-012-0036-9 – ident: 540_CR7 doi: 10.1042/BSR20170945 – volume: 15 start-page: 397 issue: 1 year: 2014 ident: 540_CR12 publication-title: Asian Pac J Cancer Prev doi: 10.7314/APJCP.2014.15.1.397 – volume: 57 start-page: 1531 issue: 11 year: 2008 ident: 540_CR22 publication-title: Gut. doi: 10.1136/gut.2008.159293 – volume: 118 start-page: c315 issue: 4 year: 2011 ident: 540_CR27 publication-title: Nephron Clin Pract doi: 10.1159/000323136 – volume: 58 start-page: 2061 issue: 7 year: 2013 ident: 540_CR6 publication-title: Dig Dis Sci doi: 10.1007/s10620-013-2591-3 – volume: 21 start-page: 142 issue: 2 year: 2009 ident: 540_CR25 publication-title: Chin J Cancer Res doi: 10.1007/s11670-009-0142-4 – volume: 134 start-page: 1570 issue: 5 year: 2008 ident: 540_CR17 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2008.02.002 – volume: 12 start-page: e65 issue: 1 year: 2016 ident: 540_CR13 publication-title: Asia Pac J Clin Oncol doi: 10.1111/ajco.12090 – volume: 228 start-page: 1017 issue: 5 year: 2013 ident: 540_CR24 publication-title: J Cell Physiol doi: 10.1002/jcp.24248 – volume: 208 start-page: 17 year: 2016 ident: 540_CR18 publication-title: Recent Results Cancer Res doi: 10.1007/978-3-319-42542-9_2 – volume: 13 start-page: 1449 issue: 2 year: 2019 ident: 540_CR20 publication-title: Diabetes Metab Syndr doi: 10.1016/j.dsx.2019.02.023 |
| SSID | ssj0017820 |
| Score | 2.2924283 |
| Snippet | Background
Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related... Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related adipocytokines,... Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several obesity-related... Abstract Background Prediabetes is associated with a high risk of colon cancer, and abdominal obesity, which can result in the secretion of several... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 63 |
| SubjectTerms | Adenomatous Polyps - blood Adenomatous Polyps - pathology Adipokine Adiponectin Adiponectin - blood Adult Aged Analgesics Analysis Basic and Clinical Endocrinology Blood pressure Blood tests Care and treatment Case-Control Studies China - epidemiology Colon cancer Colonic polyps Colonic Polyps - blood Colonic Polyps - pathology Colonoscopy Colorectal cancer Colorectal Neoplasms - blood Colorectal Neoplasms - epidemiology Colorectal Neoplasms - pathology Cytokines - blood Diabetes Endocrinology Epidemiology Exercise Family medical history Female Glucose Glucose tolerance Health aspects Health risk assessment Humans Hyperplasia Leptin Leptin - blood Male Medical prognosis Medicine Medicine & Public Health Metabolic Diseases Metabolism Middle Aged Mortality Mucosa Neoplasms, Multiple Primary - blood Neoplasms, Multiple Primary - pathology Nicotinamide Phosphoribosyltransferase - blood Obesity Physical fitness Plasma Polyps Prediabetes Prediabetic state Prediabetic State - blood Prediabetic State - epidemiology Questionnaires Research Article Resistin - blood Risk Factors rology Smoking Studies Tumors Type 2 diabetes Weight control |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9BLadOX06SoUCi0NVlZsmQf09IQCik9NJCbkMYSXdh6TXazkH-fGVvexCltL_XFRpoBPWY0M9L4E2NvS-dRDDDIMZWAXDWlzL0xdd44J9GAOQOO9jvOvunTc_X1ory4c9UX5YQN8MDDwB1FV5WmbsBr0Mo3roYGarTpyhS-Uh5o9Z3VszGYSucHhAKXzjBFpY9WtNtS5BQqkYuSm4kV6sH6f1-S79ik-_mS9w5Ne1t08pg9Sk4kPx4a_4Q9CO0e2z1Lx-RP2eY7-sS_HHfNvFu2tKS1H_mG_mLovxaUyYJv1zYco23S8hYLN2gm-zL0CTklWa_5MnJCtW7nwLvl4rpbcaRMUKwrTnu4vLsM4_7tM3Z-8uXH59M8XbCQg57Jde58hFJEDdI4Sb4iSBV0Ayqg3S5llE5BFLqAKCvvRBQenyBFCLIE0LV8znZa7MZLxusAocLQKQqplPO-jshO3Mb7RrqYsdk44BYS-jhdgrGwfRRSaTvMkcU5sjRH1mTs_ZalG6A3_kb8iWZxS0io2X0BypJNsmT_JUsZe0cyYEm3sXHg0i8K2EVCybLHdFERPlpk7GBCiToJ0-pRimxaE1YWfSf0PZGmyNibbTVxUp5bG5ZXPQ26XEZqnbEXg9BtuyQJrU4St5mI46TP05p2_rNHDCeEJnQ8MvZhFNzbZv1xSPf_x5C-Yg-LQe1yIQ7YzvryKhyiG7f2r3uNvQGdjkZE priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYIgqOUumzZpn-QUj0M48cGDfQvJNPEW1rbu7i343zuTpnv2xOvLLskEOsl8J_2FsdeldSgGmOToSkBeNKXMndZ13lgr0YFZDZbqHadf1clZ8WVezlPBbZ2OVY42MRrqpgOqkR-g50HPrWZ69qH_ldOtUbS7mq7QuMluRegylGc93yVcgrDg0k6mqNTBmmous5wSJgpUcj3xRRGy_1_D_Jdnunpq8srWafRIx_fY3RRK8qNh7e-zG759wG6fps3yh2z7DSPjn5bbZtF3LRm29j3f0rcM8d-SzrPgr20bjjk36XqLjVt0lrENI0NOR603vAucsK3bBfC-W_7u1xwpEyDrmlMll_crP1ZxH7Gz48_fP53k6ZqFHNSh3OTWBShFUCC1lRQxgiy8aqDw6L1LGaQtIODMQ5CVsyIIh4-XwntZAqhaPmZ7LbLxlPHag68wgQpCFoV1rg44nEZr5xppQ8YOxwk3kDDI6SqMpYm5SKXMsEYG18jQGhmdsbe7If0AwHEd8UdaxR0hYWfHhm71wyRVNMFWpa4bcApU4RpbQwM1RomFnrmqcJCxNyQDhjQcXw5s-lABWSSsLHNE1xXho0TG9ieUqJkw7R6lyCTLsDaXcpyxV7tuGkmn3VrfXUQaDLy0VCpjTwah27EkCbNO0mg9EccJz9OednEeccMJpwnDj4y9GwX38rX-O6XPrmfiObszGxQqF2Kf7W1WF_4Fhmkb9zLq4h_beDxO priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEA9aQXwRv922SgRBUBebTTbZfazFUoSKDxb6FpLZBA-ue0vveuB_70w2d3brB7gvdyQzsNnMZH7JJL8w9rp2Hs0AJzmmEVCqrpalN6YtO-ckBjBnwNF6x-kXfXKmPp_X55ksms7CXM_fi0Z_WNI6SVXSJIfARWluszu1kDrlZfXRNmFAtG85aflHtUnYSez8v4_B14LQzQ2SN7KkKfgcP2D3M2rkh2M3P2S3Qv-I3T3NefHHbP0VQfCF466bDYuexrD-PV_TsYX0b05bV_DX9R3H6TW5dY-Fa4yLqQxBIKdd1Su-iJxorPsZ8GEx_zEsOUpm7tUlp0VbPlyGzYLtE3Z2_Onb0UmZb1QoQR_IVel8hFpEDdI4SeAQpAq6AxUwUNcySqcgCl1BlI13IgqPT5AiBFkD6FY-ZTs9NuM5422A0OBcKQqplPO-jahO2sb7TrpYsIPNB7eQ6cbp1ou5TdOORtuxjyz2kaU-sqZgb7cqw8i18S_hj9SLW0GiyU4FaD02e52NrqlN24HXoJXvXAsdtAgIlal8ozwU7A3ZgCVnxpcDl88kYBOJFsse0s1E-GhRsP2JJDohTKs3VmTzILC0CJYQbKJMVbBX22rSpI1tfVhcJRnEWEZqXbBno9FtmySJnk6StpmY46TN05p-9j1RhBMlEyKNgr3bGO6v1_rrJ939L-k9dq8a_asUYp_trC6vwgsEaCv_MrnmT6sSNMA priority: 102 providerName: Springer Nature |
| Title | Plasma adiponectin, visfatin, leptin, and resistin levels and the onset of colonic polyps in patients with prediabetes |
| URI | https://link.springer.com/article/10.1186/s12902-020-0540-7 https://www.ncbi.nlm.nih.gov/pubmed/32393372 https://www.proquest.com/docview/2404416272 https://www.proquest.com/docview/2401817366 https://pubmed.ncbi.nlm.nih.gov/PMC7216429 https://doaj.org/article/fa8579dcb6c64bda9cdc9929472b84bc |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_tQ0K8IL4JjMpISEhAYIkTO3lAaK02TUidpolKEy-W7dhQqaSl7Sr233PnJh0ZY3loU-dcxfad73f--Bngda4NqgEGObJIbJxVOY-NlGVcac3RgWlpNY13DE_E8Sj7cp6fb0F7vFVTgYsbQzs6T2o0n3z4_evyMxr8p2Dwhfi4oLGUNKZAiABILLdhFx2ToFhsmF1NKhA1XNhsJNNYFClvJjlv_IuOmwps_v_22X85resLKq_NqgZndXQf7jUokx2s1eIBbLn6IdwZNvPoj2B1iqD5p2a6Gs-mNfV59Xu2om0O4W5CS13wW9cVw3CcuoEaE1foR0MagkZGq7CXbOoZ0V7XY8tm08nlbMFQsuFqXTAa5GWzuWsHeB_D6Ojw6-A4bk5giK3Y58tYG2_zxAvLpeYEJi3PnKhs5tCx59xznVmfiNR6Xhid-MTg5XjiHM-tFSV_Ajs1FuMZsNJZV2Bs5ROeZdqY0mN2yi2Nqbj2Eey3Fa5sQ09Op2RMVAhTCqHWbaSwjRS1kZIRvN1kma25OW4T7lMrbgSJVjskTOffVWOlyusil2VljbAiM5UubWVLBJCoMabIjI3gDemAInXEl7O62cOARSQaLXVAJxnhJZII9jqSaLS2-7jVItXqvEJwheAUZdIIXm0eU05aCFe76UWQQUwmuRARPF0r3aZInOjsOOWWHXXslLn7pB7_CJTiROGEyCSCd63iXr3Wf6v0-e1lfAF307VBxUmyBzvL-YV7iQhuaXqwLc9lD3b7hyenZ_hrIAa9MBrSCxaLn2f9b38ADOlGSg |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqVgIuiDeBAkYCIQFRm9ixkwNCLbTa0u6qQq3Um2s7Nqy0JGF3u6h_it_ITB5bUkRvzSWRH0qcGc_DHn9DyKtEG2ADcHJkGtmQ5wkLjZRZmGvNQIFpaTWudwxHYnDMv5wkJyvkd3cWBsMqO5lYC-q8tLhGvgGaBzS3iGX8sfoZYtYo3F3tUmg0bLHvzn-Byzb7sPcZ6Ps6jnd3jj4NwjarQGjFJpuH2nibRF5YJjVDA8ky7kRuuQNllTDPNLceXmQ9S42OfGTgcixyjiXWCgRfApG_xvFE6ypZ294ZHX5d7lsg-ly7dxqlYmOGqzxxiC4amkah7Gm_OknAv6rgL114OU7z0mZtrQN375DbrfFKtxpuu0tWXHGP3Bi22_P3yeIQbPEfmup8XJUFitLiPV3g6Yn6aYIRNHDXRU7By0fpUkDhAtRzXQa2KMXg7jktPUU07WJsaVVOzqsZhZYtBOyM4toxraauWzd-QI6vhQQPyWoBw3hMaOasS8Fl8xHjXBuTeeiOvaUxOdM-IJvdD1e2RT3H5BsTVXs_qVANjRTQSCGNlAzI22WXqoH8uKrxNlJx2RDRuuuCcvpNtZNfeZ0mMsutEVZwk-vM5jYDu5TL2KTc2IC8QR5QKFPg46xuj0bAEBGdS21hgiS4RBSQ9V5LkAW2X91xkWpl0UxdzJyAvFxWY0-MrytceVa3AVNPMiEC8qhhuuWQGKLkMewte-zYG3O_phh_r5HKERkKDJ6AvOsY9-Kz_vtLn1w9iBfk5uBoeKAO9kb7T8mtuJlcYRStk9X59Mw9AyNxbp63M5OS0-sWBn8Ayal8dQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBWXijcpBYyEhAREbWLHTo6lsCqPVj1QqTfLntiw0pJEu9uV-PfM5AUpD4lcdmXPSHE84_nssT8z9jyzDs0AJzk6TyCWZSZip3URl9YKDGBWg6X1jpNTdXwuP1xkF_09p6tht_uQkuzONBBLU7Xeb8rQuXiu9le0epLGNPUhyBHr6-yGpMhH2Vp1NKYRiAyuT2X-UW0SjFrO_t9H5l9C09Vtk1dyp21Imt1iOz2W5Idd599m13x1h22f9Nnyu2xzhtD4m-W2nDd1RSNb9Zpv6DBD-29BG1rw11Ylx0k3OXuFhRuMlm0ZQkNOe63XvA6cyK2rOfCmXnxvVhwle0bWFaelXN4s_bCMe4-dz959PjqO-3sWYlAHYh1bFyBLggKhrSDICEJ6VYL0GL4zEYSVEBKVQhC5s0lIHD5eJN6LDEAV4j7bqrAZDxkvPPgcZ1AhEVJa54qA6qStnSuFDRE7GD64gZ6EnO7CWJh2MpIr0_WRwT4y1EdGR-zlqNJ0DBz_En5DvTgKEnl2W1Avv5jeF02weaaLEpwCJV1pCyihQJgodepy6SBiL8gGDLk4vhzY_qQCNpHIsswh3VeEj0oitjeRRNeEafVgRaYfGlYGIRRCUJRJI_ZsrCZN2u5W-fqylUHkpYVSEXvQGd3YJEGkdYK09cQcJ22e1lTzry1xOBE1If6I2KvBcH--1l8_6e5_ST9l22dvZ-bT-9OPj9jNtHO1OEn22NZ6eekfI4Jbuyetl_4A5f4_9A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+adiponectin%2C+visfatin%2C+leptin%2C+and+resistin+levels+and+the+onset+of+colonic+polyps+in+patients+with+prediabetes&rft.jtitle=BMC+endocrine+disorders&rft.au=Deng%2C+Lili&rft.au=Zhao%2C+Xiaotong&rft.au=Chen%2C+Mingwei&rft.au=Ji%2C+Hua&rft.date=2020-05-11&rft.pub=BioMed+Central+Ltd&rft.issn=1472-6823&rft.eissn=1472-6823&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12902-020-0540-7&rft.externalDocID=A627444461 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6823&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6823&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6823&client=summon |